Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.56 |
| ▸ | PPARD | Q03181 | 7/20 | 0.56 |
| ▸ | PPARA | Q07869 | 7/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18187999 | 1.00 | FFAR4 (0.58) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL18187985 | 1.00 | FFAR4 (0.58) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL18188013 | 1.00 | FFAR4 (0.58) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL850452 | 1.00 | FFAR4 (0.58) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL5879056 | 1.00 | FFAR4 (0.58) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL18187996 | 1.00 | FFAR4 (0.58) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL3859826 | 0.98 | FFAR4 (0.55) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL21955714 | 0.96 | FFAR4 (0.62) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL21955711 | 0.96 | FFAR4 (0.62) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL21694571 | 0.96 | FFAR4 (0.62) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580636-B2 | Secondary esters, methods of making, and uses thereof | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2017-02-28 | — | — | US | claimed |
| US-20160319178-A1 | Secondary Esters, Methods of Making, and Uses Thereof | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2016-11-03 | — | — | US | claimed |
| WO-2016176243-A1 | SECONDARY ESTERS, METHODS OF MAKING, AND USES THEREOF | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2016-11-03 | — | — | WO | claimed |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2025-02-20 | — | — | US | disclosed |
| US-12090131-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2024-09-17 | — | — | US | disclosed |
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11491127-B2 | Therapeutic use of compounds | UCL BUSINESS PLC (GB) | 2022-11-08 | — | — | US | disclosed |
| US-11419839-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2022-08-23 | — | — | US | disclosed |
| EP-2737901-B1 | Therapeutic Use of Compounds | UCL BUSINESS LTD (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-20200268699-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-08-27 | — | — | US | disclosed |
| US-20200197344-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-06-25 | — | — | US | disclosed |
| US-10548866-B2 | Therapeutic use of compounds | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-2642990-B1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-9580636-B2 | Secondary esters, methods of making, and uses thereof | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160319178-A1 | Secondary Esters, Methods of Making, and Uses Thereof | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2016-11-03 | — | — | US | disclosed |
| WO-2016176243-A1 | SECONDARY ESTERS, METHODS OF MAKING, AND USES THEREOF | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-2737901-A1 | Therapeutic Use of Compounds | UCL Business PLC (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2013-11-14 | — | — | US | disclosed |
| EP-2642990-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL Business Plc. (GB) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069790-A1 | THERAPEUTIC USE OF COMPOUNDS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | FFAR4 1426/4885FFAR1 85/4885GPR84 839/4885 |
| US-20200268699-A1 | THERAPEUTIC USE OF COMPOUNDS | DEGS1, CYP11B1, SGMS1 | FFAR4 1762/4885FFAR1 149/4885GPR84 1057/4885 |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | BACE1, CPT1A, BCL6 | FFAR4 880/4885FFAR1 194/4885GPR84 849/4885 |
| US-10548866-B2 | Therapeutic use of compounds | BACE1, BCL6, BCL6B | FFAR4 935/4885FFAR1 231/4885GPR84 942/4885 |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | CYP11B1, SGMS1, PTGER1 | FFAR4 1133/4885FFAR1 66/4885GPR84 630/4885 |
| US-12090131-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | FFAR4 1426/4885FFAR1 85/4885GPR84 839/4885 |
| US-11419839-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | FFAR4 1426/4885FFAR1 85/4885GPR84 839/4885 |
| US-11491127-B2 | Therapeutic use of compounds | SGMS1, CHRM1, CYP11B1 | FFAR4 1426/4885FFAR1 85/4885GPR84 839/4885 |
| US-20200197344-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | FFAR4 1426/4885FFAR1 85/4885GPR84 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.